- Home
- EXFY vs TSHA Comparison
EXFY vs TSHA Comparison
Compare EXFY & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- TSHA
- Stock Information
- Founded
- EXFY 2008
- TSHA 2019
- Country
- EXFY United States
- TSHA United States
- Employees
- EXFY N/A
- TSHA N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- TSHA Health Care
- Exchange
- EXFY Nasdaq
- TSHA Nasdaq
- Market Cap
- EXFY 343.4M
- TSHA 313.6M
- IPO Year
- EXFY 2021
- TSHA 2020
- Fundamental
- Price
- EXFY $3.31
- TSHA $1.53
- Analyst Decision
- EXFY Buy
- TSHA Strong Buy
- Analyst Count
- EXFY 4
- TSHA 8
- Target Price
- EXFY $3.50
- TSHA $6.63
- AVG Volume (30 Days)
- EXFY 335.0K
- TSHA 2.3M
- Earning Date
- EXFY 02-20-2025
- TSHA 11-13-2024
- Dividend Yield
- EXFY N/A
- TSHA N/A
- EPS Growth
- EXFY N/A
- TSHA N/A
- EPS
- EXFY N/A
- TSHA N/A
- Revenue
- EXFY $137,440,000.00
- TSHA $9,915,000.00
- Revenue This Year
- EXFY N/A
- TSHA N/A
- Revenue Next Year
- EXFY $6.09
- TSHA N/A
- P/E Ratio
- EXFY N/A
- TSHA N/A
- Revenue Growth
- EXFY N/A
- TSHA N/A
- 52 Week Low
- EXFY $1.24
- TSHA $1.19
- 52 Week High
- EXFY $4.13
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- EXFY 47.16
- TSHA 34.16
- Support Level
- EXFY $3.07
- TSHA $1.56
- Resistance Level
- EXFY $3.68
- TSHA $1.75
- Average True Range (ATR)
- EXFY 0.17
- TSHA 0.15
- MACD
- EXFY -0.04
- TSHA -0.02
- Stochastic Oscillator
- EXFY 39.34
- TSHA 10.00
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.